Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856293 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04856293 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 25 participants.
The verdict
NCT04856293, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Bioequivalence study to evaluate the pharmacokinetics of a new crizotinib encapsulated microsphere (eMS) formulation
Interventions
- DRUG Crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-04-16 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04856293
The ClinicalTrials.gov registry entry for NCT04856293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Crizotinib is the first listed.
NCT04856293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04856293 about?
NCT04856293 is a clinical study titled "Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)". Bioequivalence study to evaluate the pharmacokinetics of a new crizotinib encapsulated microsphere (eMS) formulation
What is the current status of trial NCT04856293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-04-16. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT04856293?
The interventions under investigation include: Crizotinib (DRUG).
Who is sponsoring clinical trial NCT04856293?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.